During its first years of existence, DNDi developed an intellectual property (IP) policy to guide its R&D activities and associated contractual agreements with the following objectives:
- The need to ensure that treatments are ultimately affordable to patients who need them and that access to these treatments is equitable;
- The desire to develop drugs as public goods when possible (although DNDi will not necessarily be able to control all IP for short- and mid-term projects).
The policy, which reflects the fact that DNDi outputs are likely to have negligible commercial value and that R&D agreements will often be made with public sector entities, calls for a pragmatic approach so that decisions regarding ownership of patents and of licensing terms are made on a case-by-case basis. In building its portfolio, DNDi will continue to negotiate to guarantee the best possible conditions for patients.